Theravance Biopharma Shares Drop 26% as Ampreloxetine Trial Fails, Cuts Jobs 50%
Theravance Biopharma shares dropped 26% after its Phase III CYPRESS study of ampreloxetine failed to meet the primary endpoint, prompting program wind-down and a strategic review including potential sale. The company will slash R&D division, cut workforce by 50% and reduce operating costs 60%, targeting $70 million savings by Q3 2026.
1. Phase III Trial Failure and Stock Reaction
Theravance’s Phase III CYPRESS study of ampreloxetine in multiple system atrophy patients failed to meet its primary endpoint and did not achieve secondary endpoints, despite demonstrating biological activity and a favorable safety profile. Shares plunged 26% on the announcement, reflecting investor concern over the late-stage setback.
2. Program Wind-Down and Strategic Review
Following the trial failure, the company decided to wind down the ampreloxetine program and complete additional dataset analyses in consultation with external experts. A strategic review committee has been accelerated to explore options including a potential sale to maximize shareholder value.
3. Organizational Restructuring and Cost Savings
Theravance will shut its R&D division, reduce general and administrative staff by about 50%, and cut operating costs by roughly 60% versus its preliminary 2025 base of $110 million. These measures are expected to generate $70 million in annual savings by Q3 2026 and drive $60–$70 million in annualized cash flow when combined with Yupelri sales.
4. Financial Position and Outlook
Preliminary net sales of Yupelri reached $70.6 million in Q4 2025 (up 6% year-over-year) and $266.6 million for full-year 2025 (up 12%), including a $25 million Viatris milestone. The company received a $50 million Trelegy payment in February, ended 2025 with $326.5 million cash and no debt, and expects $400 million cash plus $100 million in milestones as Trelegy sales reach $3.51 billion in 2026.